NCT07158827Available不适用
Expanded Access to Tavapadon
AbbVie0 个研究点开始时间: 2025年9月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Exclusion Criteria:
- •There are other suitable treatment options.
- •The participant qualifies for ongoing clinical trials.
排除标准
- 未提供
研究者
相似试验
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
No Longer Available
不适用
Expanded Access to EpcoritamabLymphomaNCT05692050AbbVie
Available
不适用
Expanded Access to VenetoclaxChronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaAcute Lymphoblastic Leukemia (ALL)Plasma Cell LeukemiaMultiple MyelomaAmyloidosisNCT03123029AbbVie
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
Temporarily Not Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
